Adverse effects of co-administration of diclofenac and ondansetron on liver, heart, kidney and spleen tissues of mice

Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 427

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

AFZMED02_037

تاریخ نمایه سازی: 30 دی 1397

Abstract:

Background: Next to the curative effects of chemotherapy, it has negative effects on normal cells and organs functions. For diminution of these adverse effects, several otherdrugs are administrated in coordination with chemotherapeutic agents. Ondansetron (ODT) is a 5-HT3 receptor antagonist which is widely being used as an antiemetic agent afteroperations and chemotherapy. Diclofenac (DIC) is a nonsteroidal anti-inflammatory drug (NSAID) which is used for reducing the chronic pains of cancer. Regarding to theprotective effects of ODT on different tissues, it seems that its co-administration with DIC would reduce the toxicity effects of DIC and improve the pain relive Objectives: This study was performed to evaluate whether administration of ondansetron (ODT) ameliorated the side effects of DIC on different vital tissues of mice.Materials/Patients and Methods: To this end 52 NMRI mice were divided into six groups and the effect of administration of 100 mg/kg DIC, 1 mg/kg ODT, and 0.1, 0.5 and1 mg/kg ODT in coordination with 100 mg/kg DIC on liver, kidney, heart and spleen of animal was studied. Results: The oxidative stress (OS) studies showed that this co-administration lead to significant increase in MDA and valuablereduction in GSH. Also the histopathological analyses revealed high adverse effects of ODT-DIC interaction, especially in kidney andheart tissues. These results showed atrophic glomeruli, mononuclear cells infiltration and considerable interstitial edema in kidney and remarkable edema, hemorrhage andcongestion of vessels in heart tissues. Conclusion: These findings indicated that ODT not only did not reduce the adverse pathological effects of DIC, but also intensified these negative effects.

Authors

Azad Salimi

M.Sc. Student of Toxicology, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran

Hamid Reza Rahimi

Assistant Professor, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.

Elham Jafari

Assistant Professor, Pathology and Stem Cells Research Center, Kerman University of Medical Science, Kerman, Iran.

Mohsen Doostmohammadi

Ph.D. Candidate. Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran